Tumor News and Research

RSS
Halozyme Therapeutics, Lilly sign global collaboration and license agreement

Halozyme Therapeutics, Lilly sign global collaboration and license agreement

Mirati announces initiation of glesatinib Phase 2 clinical trial in NSCLC patients

Mirati announces initiation of glesatinib Phase 2 clinical trial in NSCLC patients

TUM scientists develop small molecule that may allow future patient-specific treatment of cancer tumours

TUM scientists develop small molecule that may allow future patient-specific treatment of cancer tumours

TSRI-led study finds potential new therapeutic approach for hard-to-treat breast cancers

TSRI-led study finds potential new therapeutic approach for hard-to-treat breast cancers

Adaptimmune begins Phase I/II study of affinity enhanced T-cell therapy targeting MAGE-A10 in NSCLC patients

Adaptimmune begins Phase I/II study of affinity enhanced T-cell therapy targeting MAGE-A10 in NSCLC patients

Endoscopic submucosal dissection appears to be effective treatment for patients with throat cancer

Endoscopic submucosal dissection appears to be effective treatment for patients with throat cancer

New discovery may soon make prostate cancer cells easier to destroy

New discovery may soon make prostate cancer cells easier to destroy

UCL Cancer Institute win $200,000 CytoFLEX Flow Cytometer from Beckman Coulter

UCL Cancer Institute win $200,000 CytoFLEX Flow Cytometer from Beckman Coulter

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

New nanotechnology approach could transform gliomas from death sentence into treatable condition

New nanotechnology approach could transform gliomas from death sentence into treatable condition

Research opens door to validation studies in multiple tumor types of liquid biopsy

Research opens door to validation studies in multiple tumor types of liquid biopsy

Family members of CUP patients at higher risk of developing CUP themselves

Family members of CUP patients at higher risk of developing CUP themselves

Multiple small doses of targeted radiation therapy more effective at destroying pituitary gland tumors

Multiple small doses of targeted radiation therapy more effective at destroying pituitary gland tumors

Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies on the way for difficult-to-treat head and neck cancer

AGA issues six new clinical practice guidelines

AGA issues six new clinical practice guidelines

Berkeley Lab researchers develop new mouse model for most common form of breast cancer

Berkeley Lab researchers develop new mouse model for most common form of breast cancer

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Study offers new view of how cancer cells transform normal cells through 'metastatic hijacking'

Study offers new view of how cancer cells transform normal cells through 'metastatic hijacking'

Study paves way for development of novel cancer therapeutics

Study paves way for development of novel cancer therapeutics

Use of tumor-treating fields along with chemotherapy improves survival in patients with brain tumor

Use of tumor-treating fields along with chemotherapy improves survival in patients with brain tumor

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.